Market Overview

ERT Expands Corporate Presence in Japan

KK Registration and Personnel Expansion Stem from Increased Adoption of ERT's Solutions in Japanese Clinical Trials

PHILADELPHIA, PA (PRWEB) January 15, 2013

ERT, a global technology-driven provider of health outcomes research services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), today announced significant milestones that reinforce its position as a leading eClinical trial solutions provider in Japan.

ERT has completed registration for Kabushiki Kaisha (KK) in Japan and has formed a fully-owned subsidiary, ERT Asia Group, Ltd. The KK registration enables ERT to broaden the local services it provides in Japan and establishes a solid foundation to expand its Asian presence. Along with this registration, ERT will grow the number of local resources in Japan that will work directly with its customers to deploy Japan-based projects. Local teams will further enhance the quality of services that ERT is known for providing.

Having already deployed solutions in over 1,200 studies in Asia, this expansion enhances ERT's capabilities to support the growing number of biopharmaceutical companies who are utilizing its eClinical solutions in trials throughout Asia. ERT is the industry leader in delivering important health outcomes research services in support of clinical trials that include the enrollment of subjects in Asia. Trusted by researchers and regulators worldwide, ERT solutions in cardiac safety, respiratory and eClinical Outcome Assessments (eCOA) – including patient, clinician and observer reported outcomes - have been used to capture primary efficacy and safety data for treatments approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

“We are pleased to have collaborated with so many global and domestic biopharmaceutical organizations on their Japanese-based clinical trials and to have delivered the valuable data they need to evaluate their products' safety and efficacy profiles,” said Robert Brown, Vice President, Business Development Asia-Pacific at ERT. “Increasing the number of local ERT resources will enable us to work more collaboratively with our customers and our excellent partners in Japan and other Asian countries to increase efficiencies in study execution and improve the integrity of data collected in clinical research.”

ERT has launched a localized version of its corporate website (http://www.ertjapan.jp) to help Japanese biopharmaceutical researchers access important information about ERT's eClinical trial solutions, capabilities, and currently available positions. Website visitors can also view and download educational content including recent industry publications, podcasts, and webinars on topics pertaining to cardiac safety, respiratory, and COA data collection via the site's comprehensive resource center.

For further information on ERT and its solutions please visit http://www.ERT.com or http://www.ertjapan.jp.

About ERT
ERT (http://www.ert.com) is a global technology-driven provider of health outcomes research solutions and services supporting biopharmaceutical and medical device organizations to achieve their new medical product development and commercialization objectives. ERT harnesses leading technology coupled with reliable processes and scientific/regulatory expertise to collect, analyze and report on clinical trial data to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical and new medical products. ERT is the acknowledged industry leader in centralized cardiac safety, respiratory efficacy services, scientific and regulatory consulting, and Clinical Outcome Assessment (COA) solutions, which includes patient, clinician, and observer reported outcomes. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10326741.htm

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free